Please use this identifier to cite or link to this item: https://dora.health.qld.gov.au/qldresearchjspui/handle/1/493
Full metadata record
DC FieldValueLanguage
dc.contributor.authorVan Den Bogaerde, J.en
dc.contributor.authorTrachter, R.en
dc.contributor.authorAuer, K.en
dc.contributor.authorSorrentino, D.en
dc.contributor.authorBassaganya-Riera, J.en
dc.date.accessioned2018-06-16T20:34:51Z-
dc.date.available2018-06-16T20:34:51Z-
dc.date.issued2014en
dc.identifier.citationFebruary 10, (2), 2014, p. 219-229en
dc.identifier.otherRISen
dc.identifier.urihttp://dora.health.qld.gov.au/qldresearchjspui/handle/1/493-
dc.description.abstractIn the last several years many biologic agents for Crohn's disease have been developed. Due to their unique molecular specificity biologics are de facto indicators of the ultimate significance of the molecule targeted by the biologic itself. Here, we have reviewed many clinical studies that have used biologics for Crohn's disease. Their results show that despite potentially sound theoretical mechanisms of action and some initially promising data, most biologics-with few notable exceptions - have failed. Pharmacologic, study design or patient-related issues might explain these findings in some studies. However in many cases clinical failure of biologics might highlight the complexity of in vivo events and the potential deficiencies of current experimental settings. Hence, these observations call for new and efficient ways of predicting drug efficacy in clinical trials based on bench research. Conceivably, computer-based pathogenetic models could be used to simulate and predict clinical studies results in vivo. 2014 Informa UK Ltd.<br />en
dc.languageenen
dc.relation.ispartofExpert Review of Clinical Immunologyen
dc.titleTranslational research and efficacy of biologics in Crohn's disease: A cautionary taleen
dc.typeArticleen
dc.identifier.doihttp://dx.doi.org/10.1586/1744666X.2014.877839en
dc.subject.keywordsbiologic agentsclinical trialsen
dc.subject.keywordscomputer-based disease modelsen
dc.subject.keywordsCrohn's diseaseen
dc.subject.keywordsCrohn's disease pathogenesisen
dc.subject.keywordsmonoclonal antibodiesen
dc.subject.keywordstranslational researchen
dc.subject.keywordsclinical trial (topic)en
dc.subject.keywordsCrohn diseaseen
dc.subject.keywordsdrug efficacyen
dc.subject.keywordsdrug mechanismen
dc.subject.keywordsdrug researchen
dc.subject.keywordsdrug targetingen
dc.subject.keywordshumanen
dc.subject.keywordsimmune responseen
dc.subject.keywordsin vivo studyen
dc.subject.keywordsnonhumanen
dc.subject.keywordsreviewen
dc.subject.keywordsstudy designen
dc.subject.keywordssystematic review (topic)en
dc.subject.keywordsTh1 cellen
dc.subject.keywordsTh17 cellen
dc.subject.keywordsalicaforsenen
dc.subject.keywordsapilimoden
dc.subject.keywordsbiological product/ct [Clinical Trial]en
dc.subject.keywordsbiological product/pd [Pharmacology]en
dc.subject.keywordsbriakinumab/ec [Endogenous Compound]en
dc.subject.keywordsdoramapimoden
dc.subject.keywordsfontolizumaben
dc.subject.keywordsgamma interferon/ec [Endogenous Compound]en
dc.subject.keywordsinterleukin 10/ec [Endogenous Compound]en
dc.subject.keywordsinterleukin 11/ec [Endogenous Compound]en
dc.subject.keywordsinterleukin 12/ec [Endogenous Compound]en
dc.subject.keywordsinterleukin 12 antibodyen
dc.subject.keywordsinterleukin 17/ec [Endogenous Compound]en
dc.subject.keywordsinterleukin 23/ec [Endogenous Compound]en
dc.subject.keywordsinterleukin 6/ec [Endogenous Compound]en
dc.subject.keywordsJanus kinase inhibitor/ec [Endogenous Compound]en
dc.subject.keywordsmitogen activated protein kinase inhibitor/ec [Endogenous Compound]en
dc.subject.keywordsnatalizumaben
dc.subject.keywordsrecombinant interleukin 10en
dc.subject.keywordsrecombinant interleukin 11en
dc.subject.keywordssecukinumaben
dc.subject.keywordssemapimoden
dc.subject.keywordstocilizumaben
dc.subject.keywordstofacitiniben
dc.subject.keywordstumor necrosis factor alpha/ec [Endogenous Compound]en
dc.subject.keywordsustekinumaben
dc.subject.keywordsvedolizumaben
dc.subject.keywordsvidofludimusen
dc.relation.urlhttp://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=emed11&AN=2014075431en
dc.identifier.risid473en
dc.description.pages219-229en
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
item.grantfulltextnone-
item.openairetypeArticle-
item.fulltextNo Fulltext-
Appears in Sites:Sunshine Coast HHS Publications
Show simple item record

Page view(s)

132
checked on Mar 29, 2024

Google ScholarTM

Check

Altmetric


Items in DORA are protected by copyright, with all rights reserved, unless otherwise indicated.